Loading…
for educational and safety purposes
Oxiracetam and Pramiracetam both come up in the same conversations; they overlap on Acetylcholine. Oxiracetam: Oxiracetam is a synthetic compound from the racetam family and a close chemical relative of piracetam; it was developed in Italy in the 1980s as a prescription drug for memory and attention problems in dementia. Pramiracetam: Pramiracetam is a laboratory-made compound in the piracetam ("racetam") family, developed by Parke-Davis as CI-879 and later sold in a few European countries as a prescription memory drug under the brand name Pramistar.
Oxiracetam is a synthetic compound from the racetam family and a close chemical relative of piracetam; it was developed in Italy in the 1980s as a prescription drug for memory and attention problems in dementia. Older European trials in dementia patients generally reported small improvements on cognitive test scores, but the modern evidence is split: a 590-patient Chinese trial in traumatic brain injury found a real benefit, while a 500-patient Korean trial found none for preventing cognitive decline after stroke, and South Korea then withdrew the drug. Nobody has established how it works; a standard 19-target receptor screen found no measurable binding at concentrations up to 30 micromolar, and no binding constant for oxiracetam at any brain receptor exists in the published literature. It remains in clinical use in China and is sold elsewhere as an unapproved powder, with a mild side-effect record but no trial evidence at all that it improves cognition in healthy people.
Pramiracetam is a laboratory-made compound in the piracetam ("racetam") family, developed by Parke-Davis as CI-879 and later sold in a few European countries as a prescription memory drug under the brand name Pramistar. It is meant to improve memory and attention; in animals it reliably increases the rate at which brain cells take up choline, a building block of the memory-related signalling chemical acetylcholine, but no receptor that it binds to has ever been identified. Human evidence is thin: a small placebo-controlled trial in men with head injuries reported better delayed recall, and a study in healthy volunteers found it partly blunted drug-induced forgetting, while a trial in Alzheimer's disease found no benefit even at high doses. The entire published literature is roughly 40 papers, most of them small, decades old, or done in rodents, so confident claims that it strongly enhances cognition in healthy people are not supported by what has actually been measured.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
increases
Upregulation (enantiomer-specific, indirect, protein-expression level)
positive modulator
Positive modulation (functional; increases agonist efficacy, not potency)
No measurable activity; this is a negative result and the best-supported target fact about the compound
Indirect presynaptic enhancement
Biphasic enhancement, with an inverted-U concentration response
Reversal of kynurenic acid antagonism
boosts
Transient activator followed by down-regulation
facilitates
enhances
Permissive requirement, not a direct target; memory effect is abolished without intact steroid signalling
raises
Normalises scopolamine-induced changes in choline permeability; increases cerebral blood flow
No measurable affinity
Increases enzyme activity without changing NOS mRNA
Inhibitor
Increases choline uptake; bell-shaped dose-response
Antiaggregant, reported as mediated mainly via inhibition of thromboxane A2 metabolism
modulates
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Oxiracetam is currently listed by more trusted vendors (3), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.